Literature DB >> 8944695

Hyperglycemia affects proximal gastric motor and sensory function during small intestinal triglyceride infusion.

G S Hebbard1, M Samsom, W M Sun, J Dent, M Horowitz.   

Abstract

Hyperglycemia slows gastric emptying in normal individuals and patients with diabetes mellitus and may affect both somatic and visceral sensation. The effects of hyperglycemia on proximal gastric motility and sensation during intraduodenal infusion of a triglyceride emulsion were evaluated using a barostat in six normal subjects during euglycemia and hyperglycemia (approximately 15 mmol/l). Isobaric distension induced greater bag volumes during hyperglycemia compared with euglycemia at 3 (452 +/- 26 vs. 343 +/- 12 ml, P < 0.05) and 4 mmHg (600 +/- 55 vs. 497 +/- 50 ml, P < 0.05) above basal pressure. During isovolumetric distension, intrabag pressure was less during hyperglycemia at 500 (2.5 +/- 0.3 vs. 3.5 +/- 0.5 mmHg above basal pressure, P < 0.05) and 600 ml (3.0 +/- 0.4 vs. 4.5 +/- 0.5 mmHg above basal pressure, P < 0.05). Perception of nausea (P < 0.05) and fullness (P < 0.05) was increased during hyperglycemia compared with euglycemia. We conclude that hyperglycemia 1) reduces proximal gastric tone during intraduodenal triglyceride infusion, an effect that may contribute to delayed gastric emptying, and 2) increases the intensity of nausea and fullness during intraduodenal triglyceride infusion and proximal gastric distension, indicative of an effect on visceral sensation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944695     DOI: 10.1152/ajpgi.1996.271.5.G814

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  26 in total

1.  Fat and esophageal sensitivity to acid.

Authors:  Maria Mangano; Paola Colombo; Paolo A Bianchi; Roberto Penagini
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

2.  Relationships between gastric accommodation and gastrointestinal sensations in healthy volunteers. A study using the barostat technique and two- and three-dimensional ultrasonography.

Authors:  M W Mundt; T Hausken; A J P M Smout; M Samsom
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

Review 3.  Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists.

Authors:  Paul Kuo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Botulinum Toxin as a Treatment for Refractory Gastroparesis: a Literature Review.

Authors:  Ashley Thomas; Bruno de Souza Ribeiro; Miguel Malespin; Silvio W de Melo
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 5.  Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus.

Authors:  Magnus Halland; Adil E Bharucha
Journal:  Clin Gastroenterol Hepatol       Date:  2015-12-21       Impact factor: 11.382

Review 6.  Diabetes and the Stomach.

Authors:  Allen A Lee; William L Hasler
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

7.  Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial.

Authors:  N J Talley; M Verlinden; D J Geenen; R B Hogan; D Riff; R W McCallum; R J Mack
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

8.  Impaired contractility and remodeling of the upper gastrointestinal tract in diabetes mellitus type-1.

Authors:  Jens Brondum Frokjaer; Soren-Due Andersen; Niels Ejskjaer; Peter Funch-Jensen; Asbjorn-Mohr Drewes; Hans Gregersen
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Authors:  Adrian Vella; Gerlies Bock; Paula D Giesler; Duane B Burton; Denise B Serra; Monica Ligueros Saylan; Carolyn F Deacon; James E Foley; Robert A Rizza; Michael Camilleri
Journal:  Clin Endocrinol (Oxf)       Date:  2008-03-10       Impact factor: 3.478

10.  Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes.

Authors:  K L Koch; W L Hasler; K P Yates; H P Parkman; P J Pasricha; J Calles-Escandon; W J Snape; T L Abell; R W McCallum; L A Nguyen; I Sarosiek; G Farrugia; J Tonascia; L Lee; L Miriel; F Hamilton
Journal:  Neurogastroenterol Motil       Date:  2016-03-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.